PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Article in European Journal of Cancer (December 2023)
The most recent citing publications are shown below. View all 63 publications that cite this research output on Dimensions.
Article in European Journal of Cancer (December 2023)
Article in Journal for ImmunoTherapy of Cancer (November 2023)
Article in Cancer Medicine (November 2023)